Developer docs
API playgroundTry for free, no card

Search company profiles

Hyfe

Full company profile

uuid003vrb3

Namestring
Hyfe
Legal namestring
Hyfe Inc.
Websiteurl
hyfe.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Hyfe Inc. is a Wilmington, Delaware-incorporated digital health company founded in 2020 that builds privacy-preserving, on-device acoustic AI for continuous cough detection and monitoring. Its proprietary two-model architecture runs entirely on-device, analyzing timestamps rather than recording audio, and has been trained on what the company describes as the world's largest cough dataset of more than 700 million samples. The product portfolio spans the CoughMonitor Suite (a wrist-worn wearable, companion app, and dashboard providing regulatory-grade cough frequency endpoints for clinical trials), ResolveDTx (a digital therapeutic for cough hypersensitivity using Behavioral Cough Suppression Therapy), the CoughPro consumer wellness app for iOS and Android, the CoughWatch wearable, and the in-development Hyfe Cough Diary positioned for FDA clearance.

Hyfe monetizes primarily through per-participant or per-study subscription contracts with pharmaceutical sponsors, CROs, and academic researchers using the CoughMonitor Suite in 50+ clinical trials and research studies; through milestone payments and royalties on the KYORIN-led ResolveDTx digital therapeutic for Japan; through SDK/API licensing into third-party platforms (including ActiGraph's FDA-cleared LEAP wearable and ObvioHealth's decentralized trial platform); and indirectly through the freemium CoughPro consumer app, which serves as both a brand-awareness funnel and a continuous data-collection layer for model retraining. Distribution combines enterprise field sales for pharma and research accounts, OEM/embedded integration for device partners, and consumer app stores for the wellness product.

The company's strategic positioning is to convert cough from an unmeasured, subjective symptom into a quantitative digital biomarker and regulatory-grade endpoint for drug development, targeting an RCC market the company estimates at roughly $9B today growing to $14-15B by 2035 with zero FDA-approved antitussive competitors. Recent strategic moves — including the KYORIN partnership, the 2026 pivotal-trial primary endpoint agreement, the ActiGraph LEAP integration, and the December 2023 transition to a non-founder CEO — indicate a deliberate shift from founder-led research to commercial and regulatory scaling.

Short descriptiontext

Hyfe is a digital health AI company that builds privacy-preserving, on-device acoustic cough detection for pharmaceutical clinical trials, academic respiratory research, and consumer wellness, anchored by its CoughMonitor Suite endpoint product and a ResolveDTx digital therapeutic for chronic cough.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
acoustic AI cough detection, respiratory digital biomarkers, clinical trial endpoints, wearable cough monitoring, digital therapeutics
Industry2 codes
PRIMARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAJ
Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Respiratory Health / Cough Monitoring AI
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1CoughMonitor Suite
TypeSubscription Recurring
Description

Continuous cough monitoring endpoints for clinical trials and drug development. Priced per-participant or per-study models depending on deployment scope, duration, level of integration and support, and regulatory and validation requirements. Used by pharmaceutical sponsors, CROs, and academic researchers.

hyfe.com
2ResolveDTx Digital Therapeutic
TypeSubscription Recurring
Description

Prescription digital therapeutic platform for cough hypersensitivity combining cough monitoring, real-time feedback loops, and behavioral cough suppression therapy. Partnership with KYORIN Pharmaceuticals for Japanese market with milestone payments and royalties.

hyfe.com
3CoughPro Consumer App
TypeFreemium
Description

Leading wellness app for monitoring cough available on iPhone and Android. Free consumer application with premium features, generating user base for brand awareness and potential upsell to clinical-grade features.

hyfe.com
4SDK/API Licensing
TypeLicensing Royalties
Description

Flexible integration into digital health ecosystems via APIs and SDKs. Hyfe's cough detection models integrated into third-party platforms and devices such as ActiGraph's LEAP wearable.

hyfe.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1CoughMonitor Suite - Clinical Trials
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Per-participant or per-study pricing models depending on deployment scope. Quote-based for enterprise clinical trial engagements.

hyfe.com
2CoughPro Consumer App
ModelFreemiumBilling cadenceMonthly
Notes

Free consumer application available on iPhone and Android with premium wellness features

hyfe.com
3SDK/API Integration
ModelOtherBilling cadenceMulti-year contract
Notes

Flexible integration pricing for embedded deployment within third-party digital health or wearable platforms

hyfe.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1CoughMonitor Suite
Description

Continuous cough monitoring endpoints for clinical trials and drug development. Objective, validated, and regulatory-ready.

hyfe.com
+4 more records
Core offering1 text field

Hyfe builds a privacy-preserving, on-device acoustic AI platform that detects and monitors cough sounds without recording audio. Its CoughMonitor Suite provides continuous, regulatory-grade cough frequency endpoints for clinical trials and drug development, while ResolveDTx delivers prescription digital therapeutics for chronic cough, and CoughPro offers a consumer wellness app. The company serves pharmaceutical sponsors, CROs, academic researchers, and individuals with a platform-plus-products architecture centered on transforming cough into a quantifiable digital biomarker.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 41.8% reduction in cough frequency in DTx proof-of-concept study
+5 more records
Product overview1 text field

Hyfe is a digital biomarker and digital endpoint company offering a platform-plus-products architecture centered on privacy-preserving, on-device AI cough detection. The core technology transforms ambient sound into clinically meaningful, quantitative cough data without recording audio. The product portfolio includes: (1) CoughMonitor Suite — the primary research tool for clinical trials, comprising CoughWatch wearable, Companion App, and Dashboard; (2) ResolveDTx — a digital therapeutic platform for chronic cough using Behavioral Cough Suppression Therapy; (3) CoughPro — a consumer wellness app for individual cough tracking; and (4) Hyfe Cough Diary — an FDA-clearance-track medical device. Products share core AI detection technology while targeting different segments: pharma/clinical research (CoughMonitor Suite), patients/providers (ResolveDTx), and consumers (CoughPro). An SDK enables third-party platform integration.

Product and service1 record
1CoughMonitor Suite
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-24
Description

Strategic partnership for development and commercialization of the world's first prescription digital therapeutic to treat chronic cough in the Japanese market. Built on proven principles of Behavioral Cough Suppression Therapy (BCST) and powered by Hyfe's advanced cough monitoring technology. Includes milestone payments and royalties. This collaboration marks a significant milestone in leveraging advanced digital therapeutics to address a debilitating condition affecting millions worldwide.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-28
Description

Formal product launch of the ActiGraph-Hyfe combined digital health solution on ActiGraph's LEAP wearable platform. Integration of Hyfe's cough detection into ActiGraph's FDA-cleared wearable for clinical research. Hyfe's cough detection models run natively in Ametris' category-leading LEAP device.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2022-07-19
Description

Partnership to integrate Hyfe's AI cough tracker into Merck's consumer disease education efforts targeting an estimated 12 million U.S. adults with chronic cough. Joint marketing and education collaboration.

Strategic tierMinorTypeOthers
Description

Hyfe joined the Creative Destruction Lab accelerator program in 2021 for business development and mentorship support.

Strategic tierMinorTypeOthers
Description

Hyfe joined the Plug and Play accelerator program in February 2021 and participated in their Health Engine Accelerator programs. Closed ~$1M seed round with participation from Plug and Play Ventures.

6Health Engine Accelerator
Strategic tierMinorTypeOthers
Description

Hyfe joined the Health Engine Accelerator program in 2021 for healthcare startup development and validation support.

hyfe.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Year-long respiratory research trial partnership with University of Navarra, Zizur's Health Center, and Montreal University Hospital Center using Hyfe's app.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1VitalConnect
TypeEmerging player
Description

VitalConnect provides FDA-cleared biosensor patches and a remote cardiac/respiratory monitoring platform used in clinical trials and hospital RPM. Comparable as an RPM hardware + cloud platform vendor whose channels overlap with Hyfe's pharma and clinical research customers.

TypeBroad incumbent
Description

ResMed is the global leader in connected respiratory care (sleep apnea, COPD, asthma) with cloud-connected devices, RPM infrastructure, and large pharma services. Comparable as a broad incumbent whose respiratory franchise could expand into cough monitoring and digital endpoints.

TypeEmerging player
Description

Cohero Health develops connected respiratory devices and RPM platforms for asthma and COPD patients. Comparable as a digital respiratory health player using connected devices and patient-reported data, though with a different sensor approach than Hyfe's acoustic AI.

TypeDirect peer
Description

Strados Labs develops AI-enabled wearable respiratory monitoring (RESP® Biosensor) that captures lung sounds including cough. Directly comparable to Hyfe in using acoustic AI and wearables to objectively measure cough and other respiratory biomarkers for clinical trials and remote monitoring.

TypeEmerging player
Description

Sonavi Labs makes a FDA-cleared AI-powered digital stethoscope (Feelix) for auscultation and respiratory/cough analysis. Comparable in combining acoustic AI with a clinical-grade hardware device for respiratory assessment.

TypeDirect peer
Description

ActiGraph is a partner of Hyfe and a leading clinical-grade wearable (LEAP) and digital health platform for clinical research and trial endpoints. Comparable as a wearable + endpoint infrastructure vendor serving pharma and academic sponsors — and an integration partner whose installed base amplifies Hyfe's distribution.

TypeDirect peer
Description

ResApp (acquired by Pfizer) developed AI algorithms to analyze cough and respiratory sounds for disease diagnosis and monitoring. Highly comparable to Hyfe's cough-detection AI for clinical and telehealth use cases.

TypeBroad incumbent
Description

Propeller Health, now part of ResMed, is a leading digital respiratory health platform for asthma and COPD using connected inhalers and RPM. Comparable as a digital respiratory health platform serving pharma and providers, though its focus is inhaler adherence rather than cough.

TypeBroad incumbent
Description

Philips has a large respiratory care portfolio (ventilators, CPAP, sleep & respiratory RPM). Comparable as a broad incumbent with the clinical relationships, regulatory footprint, and device installed base to enter cough monitoring and digital endpoints.

TypeDirect peer
Description

Eko Health combines digital stethoscopes with AI to analyze heart and lung sounds, including cough and respiratory abnormalities. Directly comparable as an AI-driven acoustic cardiopulmonary analysis platform with FDA-cleared devices used in clinical settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyfe

Digital Respiratory Health / Cough Monitoring AIhyfe.com

Hyfe is a digital health AI company that builds privacy-preserving, on-device acoustic cough detection for pharmaceutical clinical trials, academic respiratory research, and consumer wellness, anchored by its CoughMonitor Suite endpoint product and a ResolveDTx digital therapeutic for chronic cough.

What Hyfe does

Hyfe Inc. is a Wilmington, Delaware-incorporated digital health company founded in 2020 that builds privacy-preserving, on-device acoustic AI for continuous cough detection and monitoring. Its proprietary two-model architecture runs entirely on-device, analyzing timestamps rather than recording audio, and has been trained on what the company describes as the world's largest cough dataset of more than 700 million samples. The product portfolio spans the CoughMonitor Suite (a wrist-worn wearable, companion app, and dashboard providing regulatory-grade cough frequency endpoints for clinical trials), ResolveDTx (a digital therapeutic for cough hypersensitivity using Behavioral Cough Suppression Therapy), the CoughPro consumer wellness app for iOS and Android, the CoughWatch wearable, and the in-development Hyfe Cough Diary positioned for FDA clearance.

Hyfe monetizes primarily through per-participant or per-study subscription contracts with pharmaceutical sponsors, CROs, and academic researchers using the CoughMonitor Suite in 50+ clinical trials and research studies; through milestone payments and royalties on the KYORIN-led ResolveDTx digital therapeutic for Japan; through SDK/API licensing into third-party platforms (including ActiGraph's FDA-cleared LEAP wearable and ObvioHealth's decentralized trial platform); and indirectly through the freemium CoughPro consumer app, which serves as both a brand-awareness funnel and a continuous data-collection layer for model retraining. Distribution combines enterprise field sales for pharma and research accounts, OEM/embedded integration for device partners, and consumer app stores for the wellness product.

The company's strategic positioning is to convert cough from an unmeasured, subjective symptom into a quantitative digital biomarker and regulatory-grade endpoint for drug development, targeting an RCC market the company estimates at roughly $9B today growing to $14-15B by 2035 with zero FDA-approved antitussive competitors. Recent strategic moves — including the KYORIN partnership, the 2026 pivotal-trial primary endpoint agreement, the ActiGraph LEAP integration, and the December 2023 transition to a non-founder CEO — indicate a deliberate shift from founder-led research to commercial and regulatory scaling.

Hyfe firmographics

Firmographics
Name
Hyfe
Legal name
Hyfe Inc.
Website
https://hyfe.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Hyfe is a digital health AI company that builds privacy-preserving, on-device acoustic cough detection for pharmaceutical clinical trials, academic respiratory research, and consumer wellness, anchored by its CoughMonitor Suite endpoint product and a ResolveDTx digital therapeutic for chronic cough.
Ownership category
akta.pro rank

Hyfe industry classification

Industry
Product category
Digital Respiratory Health / Cough Monitoring AI
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAFAB
Respiratory & Sleep RPM (COPD, asthma, sleep apnea)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAJ
Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Acoustic AI cough detection
  • Respiratory digital biomarkers
  • Clinical trial endpoints
  • Wearable cough monitoring
  • Digital therapeutics

Where Hyfe is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hyfe business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CoughMonitor Suite: Continuous cough monitoring endpoints for clinical trials and drug development. Priced per-participant or per-study models depending on deployment scope, duration, level of integration and support, and regulatory and validation requirements. Used by pharmaceutical sponsors, CROs, and academic researchers.
  2. ResolveDTx Digital Therapeutic: Prescription digital therapeutic platform for cough hypersensitivity combining cough monitoring, real-time feedback loops, and behavioral cough suppression therapy. Partnership with KYORIN Pharmaceuticals for Japanese market with milestone payments and royalties.
  3. CoughPro Consumer App: Leading wellness app for monitoring cough available on iPhone and Android. Free consumer application with premium features, generating user base for brand awareness and potential upsell to clinical-grade features.
  4. SDK/API Licensing: Flexible integration into digital health ecosystems via APIs and SDKs. Hyfe's cough detection models integrated into third-party platforms and devices such as ActiGraph's LEAP wearable.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCoughMonitor Suite - Clinical Trials
FreemiumMonthlyCoughPro Consumer App
OtherMulti-year contractSDK/API Integration

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Hyfe product offering

Product offering

Core offering

Hyfe builds a privacy-preserving, on-device acoustic AI platform that detects and monitors cough sounds without recording audio. Its CoughMonitor Suite provides continuous, regulatory-grade cough frequency endpoints for clinical trials and drug development, while ResolveDTx delivers prescription digital therapeutics for chronic cough, and CoughPro offers a consumer wellness app. The company serves pharmaceutical sponsors, CROs, academic researchers, and individuals with a platform-plus-products architecture centered on transforming cough into a quantifiable digital biomarker.

Product overview

Hyfe is a digital biomarker and digital endpoint company offering a platform-plus-products architecture centered on privacy-preserving, on-device AI cough detection. The core technology transforms ambient sound into clinically meaningful, quantitative cough data without recording audio. The product portfolio includes: (1) CoughMonitor Suite — the primary research tool for clinical trials, comprising CoughWatch wearable, Companion App, and Dashboard; (2) ResolveDTx — a digital therapeutic platform for chronic cough using Behavioral Cough Suppression Therapy; (3) CoughPro — a consumer wellness app for individual cough tracking; and (4) Hyfe Cough Diary — an FDA-clearance-track medical device. Products share core AI detection technology while targeting different segments: pharma/clinical research (CoughMonitor Suite), patients/providers (ResolveDTx), and consumers (CoughPro). An SDK enables third-party platform integration.

Differentiator

Problem solved

Functional benefit

Brands

  • CoughMonitor Suite: Continuous cough monitoring endpoints for clinical trials and drug development. Objective, validated, and regulatory-ready.
  • ResolveDTx
  • CoughPro
  • CoughWatch
  • Cough Diary

Products and services

  • CoughMonitor Suite

Quantifiable outcome

  • 41.8% reduction in cough frequency in DTx proof-of-concept study
  • +5 more outcomes

Companies that use Hyfe

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Hyfe technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature8 records

Hyfe partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • KYORIN Pharmaceutical Co. Ltd.flagshipStrategic or Co-development Partner · 24 February 2025Strategic partnership for development and commercialization of the world's first prescription digital therapeutic to treat chronic cough in the Japanese market. Built on proven principles of Behavioral Cough Suppression Therapy (BCST) and powered by Hyfe's advanced cough monitoring technology. Includes milestone payments and royalties. This collaboration marks a significant milestone in leveraging advanced digital therapeutics to address a debilitating condition affecting millions worldwide.
  • ActiGraphcoreTechnology or Integration · 28 January 2025Formal product launch of the ActiGraph-Hyfe combined digital health solution on ActiGraph's LEAP wearable platform. Integration of Hyfe's cough detection into ActiGraph's FDA-cleared wearable for clinical research. Hyfe's cough detection models run natively in Ametris' category-leading LEAP device.
  • MerckcoreGTM or Marketing Partner · 19 July 2022Partnership to integrate Hyfe's AI cough tracker into Merck's consumer disease education efforts targeting an estimated 12 million U.S. adults with chronic cough. Joint marketing and education collaboration.
  • Creative Destruction LabminorOthersHyfe joined the Creative Destruction Lab accelerator program in 2021 for business development and mentorship support.
  • Plug and Play VenturesminorOthersHyfe joined the Plug and Play accelerator program in February 2021 and participated in their Health Engine Accelerator programs. Closed ~$1M seed round with participation from Plug and Play Ventures.
  • Health Engine AcceleratorminorOthersHyfe joined the Health Engine Accelerator program in 2021 for healthcare startup development and validation support.
  • University of NavarraminorStrategic or Co-development PartnerYear-long respiratory research trial partnership with University of Navarra, Zizur's Health Center, and Montreal University Hospital Center using Hyfe's app.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Hyfe competitors and assessment

Company assessment

Emerging players

  • VitalConnect: VitalConnect provides FDA-cleared biosensor patches and a remote cardiac/respiratory monitoring platform used in clinical trials and hospital RPM. Comparable as an RPM hardware + cloud platform vendor whose channels overlap with Hyfe's pharma and clinical research customers.
  • Cohero Health: Cohero Health develops connected respiratory devices and RPM platforms for asthma and COPD patients. Comparable as a digital respiratory health player using connected devices and patient-reported data, though with a different sensor approach than Hyfe's acoustic AI.
  • Sonavi Labs: Sonavi Labs makes a FDA-cleared AI-powered digital stethoscope (Feelix) for auscultation and respiratory/cough analysis. Comparable in combining acoustic AI with a clinical-grade hardware device for respiratory assessment.

Broad incumbents

  • ResMed: ResMed is the global leader in connected respiratory care (sleep apnea, COPD, asthma) with cloud-connected devices, RPM infrastructure, and large pharma services. Comparable as a broad incumbent whose respiratory franchise could expand into cough monitoring and digital endpoints.
  • Propeller Health (ResMed): Propeller Health, now part of ResMed, is a leading digital respiratory health platform for asthma and COPD using connected inhalers and RPM. Comparable as a digital respiratory health platform serving pharma and providers, though its focus is inhaler adherence rather than cough.
  • Philips Respiratory Care: Philips has a large respiratory care portfolio (ventilators, CPAP, sleep & respiratory RPM). Comparable as a broad incumbent with the clinical relationships, regulatory footprint, and device installed base to enter cough monitoring and digital endpoints.

Direct peers

  • Strados Labs: Strados Labs develops AI-enabled wearable respiratory monitoring (RESP® Biosensor) that captures lung sounds including cough. Directly comparable to Hyfe in using acoustic AI and wearables to objectively measure cough and other respiratory biomarkers for clinical trials and remote monitoring.
  • ActiGraph: ActiGraph is a partner of Hyfe and a leading clinical-grade wearable (LEAP) and digital health platform for clinical research and trial endpoints. Comparable as a wearable + endpoint infrastructure vendor serving pharma and academic sponsors — and an integration partner whose installed base amplifies Hyfe's distribution.
  • ResApp Health (Pfizer): ResApp (acquired by Pfizer) developed AI algorithms to analyze cough and respiratory sounds for disease diagnosis and monitoring. Highly comparable to Hyfe's cough-detection AI for clinical and telehealth use cases.
  • Eko Health: Eko Health combines digital stethoscopes with AI to analyze heart and lung sounds, including cough and respiratory abnormalities. Directly comparable as an AI-driven acoustic cardiopulmonary analysis platform with FDA-cleared devices used in clinical settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hyfe social profiles

Digital presence

Hyfe compliance and trust

Trust signal

Compliance3 records

Hyfe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyfe leadership team

Management profile

Number of profiles

Profiles7 records

Hyfe funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyfe M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyfe

What does Hyfe do?

Hyfe builds a privacy-preserving, on-device acoustic AI platform that detects and monitors cough sounds without recording audio. Its CoughMonitor Suite provides continuous, regulatory-grade cough frequency endpoints for clinical trials and drug development, while ResolveDTx delivers prescription digital therapeutics for chronic cough, and CoughPro offers a consumer wellness app. The company serves pharmaceutical sponsors, CROs, academic researchers, and individuals with a platform-plus-products architecture centered on transforming cough into a quantifiable digital biomarker.

Is Hyfe a public or private company?

Hyfe is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hyfe founded?

Hyfe was founded in 2020. It employs 11 to 50 people.

Where is Hyfe based?

Hyfe is headquartered in Wilmington, United States, in the North America region.

How does Hyfe make money?

Four revenue lines are on record. CoughMonitor Suite is the primary driver. The others are resolveDTx Digital Therapeutic, coughPro Consumer App and SDK/API Licensing.

Who are Hyfe's main competitors?

Emerging players on record are VitalConnect, Cohero Health and Sonavi Labs. Broad incumbents are ResMed, Propeller Health (ResMed) and Philips Respiratory Care. Direct peers are Strados Labs, ActiGraph, ResApp Health (Pfizer) and Eko Health.

Does Hyfe have an API?

Yes. Hyfe provides API-based access to derived cough data for downstream analysis. Typical formats support standard statistical workflows (e.g., CSV or structured JSON outputs). The API enables integration of cough data into EDC systems, data warehouses, or analytics platforms. Hyfe also offers SDKs for flexible integration into digital health ecosystems.

What industry is Hyfe in?

Hyfe's product category is Digital Respiratory Health / Cough Monitoring AI. Its primary akta.pro industry code is HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea), with a secondary code of HLACAPAJ, Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSC Therapeutics Initiates REACH2 Trial for Refractory Chronic CoughSC Therapeutics initiated the REACH2 trial for its lead product candidate SC0032 in patients with refractory chronic cough. The randomized, placebo-controlled study will run for three weeks with a four-week follow-up to test durability of effect. The trial is conducted at three UK hospitals.EIN PresswireHyfe Cough Monitoring Primary Endpoint in Pivotal Clinical Trial for First Digital Therapeutic to Treat Chronic CoughHyfe Inc. announced regulatory agreement with Japan's PMDA to use its CoughMonitor Suite as the primary endpoint in a pivotal trial for a chronic cough digital therapeutic co-developed with KYORIN Pharmaceutical. The wrist-worn wearable has been used in over 55 studies, and PMDA approval would make it the world's first prescription digital therapeutic for chronic cough.PR NewswireDisrupting Chronic Cough: Julian Circo Brings AI to the World's Oldest SymptomJulian Circo, Co-Founder of Hyfe, appeared on the Disruption Interruption podcast to discuss how his company uses acoustic AI to transform coughing into an objective health biomarker, addressing a long-standing diagnostic gap in respiratory medicine. Hyfe has built the world's largest cough dataset with over 700 million samples collected through a consumer app launched during the pandemic, enabling the company to distinguish coughs from background noise and create a frequency chart similar to an ECG. The company is also pioneering a digital therapeutic for chronic cough sufferers, reporting 40% efficacy in behavioral cough suppression therapy.pharmaphorumMolecules, DTx, and a breakthrough in chronic coughKyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic for chronic cough and launch it in Japan, representing a concrete commercial partnership in the DTx space. An analysis piece by Hyfe's chief medical officer argues that digital therapeutics can address the scalability limitations of behavioural cough suppression therapy while also synergistically complementing pharmacologic treatments for the estimated 6-8 million US sufferers of refractory chronic cough. The article contends that the combination of molecules and digital tools may finally deliver an effective treatment for a condition that has seen decades of failed drug development, with GSK and Trevi Therapeutics among the closest candidates in the pipeline.outsourcing-pharma.comRemote trials, real challenges: The quest for accurate cough monitoringDr Peter Small of Hyfe AI discusses the challenges and advances in automated cough monitoring for clinical trials. He notes regulatory uncertainty, with the FDA having issues with 24-hour cough monitoring, and predicts cough monitors will become ubiquitous on medical and consumer devices. He also foresees cough monitoring becoming standard in remote patient monitoring and hospital-at-home care.Venture Capital Access OnlineHyfé Raises $9 Million to Create Future Feedstocks for BiomanufacturingHyfé announced an oversubscribed $9 million seed investment led by Synthesis Capital to advance its technology for converting food processing wastewater into biomanufacturing feedstocks. The company, founded by former ExxonMobil and LanzaTech engineers, plans to use the funds to expand its workforce and progress toward pilot-scale demonstrations. This funding supports Hyfé's goal of providing sustainable, cost-effective carbon sources for the bioeconomy while reducing wastewater treatment costs for food manufacturers.ErlystageHealthcare at HomeStartups like Dispatch Health, Treat At Home, and Hyfe are providing in-home urgent care and telemedicine services, reducing reliance on hospitals. Dispatch Health charges $5–$50 after insurance, while Treat At Home offers telemedicine for Rs.1000. The article argues these services are necessary as hospitals become overwhelmed and families are smaller.